

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: May 11, 2016</p>	
<p>Re.: Press Release.</p>	


Dear Sir / Madam,

We enclose herewith a copy of press release dated May 11, 2016 under the title **Zydus receives final approval from the USFDA for Glyburide Tablets** which will be produced at the group's formulations manufacturing facility at Baddi. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For Cadila Healthcare Limited


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Glyburide Tablets

Ahmedabad, 11 May 2016

Zydus Cadila has received the final approval from the USFDA to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg. Glyburide, which is an anti-diabetic drug will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
